As US measles cases rise, biotech firms start developing new treatments

As US measles cases rise, biotech firms start developing new treatments. The US is making measles great again, so treatment options are needed for the most vulnerable.

A apuração publicada por arstechnica.com vira base para uma leitura editorial direta e contextualizada.

Trechos de apoio da pauta: Up until recently, measles vaccination has been so effective that there’s been little medical or financial incentive to develop treatments for the disease. But as measles cases hit a 35-year high and vaccination rates continue to decline in the US, a handful of biotech companies and academic groups have started working on measles treatments for those infected with the virus as well as vulnerable individuals needing short-term protection.

• Ponto de atenção: measles.
• Ponto de atenção: cases.
• Ponto de atenção: rise.

Em resumo, a leitura editorial acompanha o impacto do tema no nicho Tech.